Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$15.27 ▼ -0.53
(-3.35%)
MKT CAP: $697.1M • VOL: 413.8K
52W L $13 52W H $28
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$13
MEDIAN
$17
MEAN
$17
HIGH
$21
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ATTO TAPE
ATTO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $18.48 | $17.56 | 2025-02-14 | $13.90 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $19.24 | $18.02 | 2025-02-06 | $14.35 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $17.41 | $16.80 | 2025-01-29 | $14.66 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $15.58 | — | 2025-01-17 | $14.96 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $13.44 | $14.51 | 2025-01-09 | $13.59 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $18.17 | $15.88 | 2024-12-18 | $13.28 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $14.81 | $15.42 | 2024-12-04 | $14.20 | -4.3% | 48% | C |